LOS ANGELES, CA--(Marketwire - April 22, 2010) - MMR Information Systems, Inc. (
Dr. Bruce Garrett, President and Chief Operating Officer of GRSworldwide (GRS), MMR's biotech consultants on its anti-CD20 antibody assets, based in Rockville, Maryland, said, "These assets could show promise for treating a variety of medical conditions, chief among them cancer, rheumatoid arthritis and potentially others. Based on existing data, GRS believes this particular formulary has the potential to become one of the best anti-CD20 monoclonal antibodies in its class."
Robert H. Lorsch, Chairman and CEO of MMR Information Systems, Inc., noted, "Our primary business is the development, marketing and sales of the Company's personal and professional health IT products, however, maximizing shareholder value is always a primary focus. It now appears that monetizing pre-merger assets such as the anti-CD20 antibodies and licensing the use of clinical trials data and patient samples from FavId® trials, may represent a unique opportunity to generate shareholder value that was not contemplated as part of the Company's original post-merger business plan, particularly in the area of cancer research."
Earlier this month, MMR signed an agreement with the Lymphoma Research Foundation (LRF) under which the two organizations will work in good faith regarding the use of pre-merger Favrille intellectual property, including more than 150 lymphoma tumor samples accumulated by the Company as part of its research on which more than $140 million dollars was spent on the development of the FavId vaccine.
While the Company remains focused on its core business, including the MyMedicalRecords Personal Health Record and MMRPro for physician practices, it understands that clinical data and patient samples from the Company's trials may be valuable to universities, biopharmaceutical companies and research organizations, among other institutions. Additionally, the Company's anti-CD20 antibody assets could represent a potential candidate for the next generation Rituximab. Rituximab, which is sold under the brand name Rituxan® in the United States by Biogen Idec and Genentech (wholly owned member of the Roche Group) and under the name MabThera® by Roche in the rest of the world except Japan, where it is co-marketed by Chugai and Zenyaku Kogyo Co. Ltd., is one of the world's most successful monoclonal antibodies with reported 2009 sales of USD $5.6 billion.
MMR INFORMATION SYSTEMS, INC.
MMR Information Systems, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. ("MMR"), provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, unions and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. The Company's professional offering, MMRPro, is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMR Information Systems, Inc. and its products, visit www.mymedicalrecords.com and view the videos at www.mymedicalrecordsonline.com/videos.
FORWARD-LOOKING STATEMENTS
Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements regarding the Company's assets including but not limited to its primary Health IT businesses, FavId and data from vaccine and clinical trials, and anti-CD20 antibody assets. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the development and approval of biotechnology/biopharmaceutical product candidates and Health IT products and additional risks discussed in the Company's filings with the Securities and Exchange Commission. All subsequent written and oral forward-looking statements attributable to the Company (or any person acting on the Company's behalf) are qualified by the cautionary statements in this notice. MMR Information Systems, Inc. is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.
Contact Information:
CONTACT: Bobbie Volman
MMR Information Systems, Inc.
(310) 476-7002, Ext. 2005
bvolman@mmrmail.com
Michael Selsman
Public Communications Co.
(310) 553-5732
ms@publiccommunications.biz